Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of LBL-024 for Platinum-Resistant Ovarian Cancer

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an update.

Nanjing Leads Biolabs has begun dosing the first patient in a Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) in combination with paclitaxel for platinum-resistant ovarian cancer, an open-label, multi-centre study led by the Cancer Hospital of the Chinese Academy of Medical Sciences across several sites in China. The company highlights LBL-024 as the first 4-1BB–targeting therapy to reach a registrational stage globally for extra-pulmonary neuroendocrine carcinoma, supported by encouraging efficacy and safety data from prior China trials, recent Chinese and U.S. regulatory recognitions including a breakthrough therapy designation and orphan drug status, and early signals of activity across multiple difficult-to-treat tumor types, reinforcing its ambition to position LBL-024 as a broad-spectrum anti-tumor immunotherapy candidate despite ongoing development risks.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, particularly immuno-oncology drugs targeting hard-to-treat solid tumors. Its pipeline includes the bispecific antibody Opamtistomig (LBL-024), designed to target PD-L1 and 4-1BB, with a strategic emphasis on cancers with high unmet medical needs such as extra-pulmonary neuroendocrine carcinoma and other solid tumors resistant to existing immunotherapies.

Average Trading Volume: 610,672

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.98B

For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.